Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA UCSD
Dates
study started
estimated completion

Description

Summary

The main purpose of this study is to investigate the safety of LY3405105 in participants with advanced cancer. The study has two parts (A and B). Participants will only enroll in one part.

Official Title

A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors

Keywords

Solid Tumor

Eligibility

You can join if…

Open to people ages 18 years and up

  • Have histological or cytological evidence of a diagnosis of a solid tumor cancer that is advanced and/or metastatic
  • Have available archived tissue for exploratory biomarker analysis
  • Have adequate organ function
  • Have discontinued all previous treatments for cancer and recovered from their side effects
  • Are able to swallow capsules/tablets

You CAN'T join if...

  • Have symptomatic central nervous system (CNS) malignancy or metastasis
  • Have symptomatic human immunodeficiency virus (HIV), Hepatitis A, B, or C
  • Have congestive heart failure
  • Are breastfeeding

Locations

  • University of California - San Diego
    La Jolla California 92037-0845 United States
  • UCLA Medical Center
    Los Angeles California 90024 United States
  • UCLA Medical Center
    Los Angeles California 90095 United States

Details

Status
currently not accepting new patients, but might later
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
A Study of LY3405105 in Participants With Advanced Cancer
ID
NCT03770494
Phase
Phase 1
Study Type
Interventional
Last Updated